TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Bio Vitos Pharma AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Turnover |
111
|
2,996
|
1,320 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-20,069
|
-12,867
|
-14,900 |
| EBITDA |
-3,318
|
-3,504
|
-7,775 |
| Total assets |
16,316
|
33,919
|
26,450 |
| Current assets |
379
|
5,112
|
5,222 |
| Current liabilities |
395
|
1,008
|
1,527 |
| Equity capital |
15,921
|
32,911
|
24,923 |
| - share capital |
5,733
|
4,278
|
3,093 |
| Employees (average) |
1
|
1
|
5 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Solvency |
97.6%
|
97.0%
|
94.2% |
| Turnover per employee |
111
|
2,996
|
264 |
| Profit as a percentage of turnover |
-18080.2%
|
-429.5%
|
-1128.8% |
| Return on assets (ROA) |
-123.0%
|
-37.9%
|
-56.3% |
| Current ratio |
95.9%
|
507.1%
|
342.0% |
| Return on equity (ROE) |
-126.1%
|
-39.1%
|
-59.8% |
| Change turnover | |||
| Change turnover % | 18% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % | -17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.